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ABSTRACT 
 
Chronic wounds are such wounds which do not heal through normal physiological healing 
process. Different bandages and medicines have been tried to heal such wounds but these are 
very recalcitrant to get healed. Millions of people are being affected by these and hence need 
special attention. Major reasons for pathogenesis of chronic wounds mainly include 
insufficient and disorganized extracellular matrix (ECM), insufficient angiogenesis, 
adipogenesis, and some ulcers caused by chronic infections, that all together lead to chronic 
inflammations and the persistence of these wounds. Therefore, in my study, I targeted all the 
above mentioned causatives of chronic ulcers by the preparation of ECM based composite 
scaffolds which were then characterized through swelling, water vapor permeability, 
biodegradability, in – vitro cytotoxicity, XRD, FTIR, etc. Phytochemicals being famous for 
their medicinal values have been used since ages. Therefore, Curcumin, a well known 
phytochemical was incorporated in the prepared film to study the drug release kinetics. The 
effect of the phytochemicals was studied over angiogenesis, adipogenesis and over special 
category of ulcers through in silico analysis. The selected phytochemicals were also extracted 
as a crude extract through the soxhlet method, which were then screened through biochemical 
tests. Concentration of these phytochemicals was also optimized for the stem cell 
proliferation and was found to be compatible with them. 
  
Keywords- Chronic inflammations, angiogenesis, extracellular matrix, Polymer, 
Proliferation, Phytochemicals 
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INTRODUCTION 
Skin, being the first barrier in the body defense plays a very important role in preventing the 
body from various infections, diseases and disorders. Any injury to this protective layer, that is, 
skin lead to different types of wounds which depend upon the degree of the injury caused. 
Healing of such injuries is a natural process which begins soon after the injury and completely 
recovers the injured or wounded tissue. This is a general phenomenon which includes various 
interlinked and overlapping phases: Hemostasis and inflammation, Re-epithelialization and 
Remodeling.  
Hemostasis and Inflammation stage includes the initial breakage of the epithelial tissue lining 
which activates the clotting factors. Fibrinogen begins the clotting of blood through the fibrin 
formation. Inflammation starts within 24 hours of hemostasis and can be extended upto 49-72 
hours. This phase causes dilation of the blood vessels, thus initiating the infiltration of the 
inflammatory cells. Platelets, itself being released from thrombus, release the growth factors like 
Platelet derived growth factor (PDGF) and Transforming growth factor – β (TGF-β). The above 
mentioned infiltration of inflammatory cells includes the chemotactic movement and the 
proliferation of the macrophages and the neutrophils. Both, neutrophils and macrophages eat 
away the debris of the necrotic tissue[1]. Unlike neutrophils, the macrophages release certain 
rowth factors and cytokines such as interleukins (IL-1, IL-6, and IL-8), PDGF, TGF-β, Insulin 
growth factor (IGF), Vascular Endothelial Growth Factor (VEGF), and Fibroblast Growth Factor 
(FGF), which inturn helps in the revival and proliferation of the cells near the wound site like 
endothelial cells and the fibroblast cells along with more macrophages[2]. 
Proliferative stage completely rotates around the fibroblast cells which produce collagen, not 
only to provide structural support but also replaces the matrix formed from the composite of 
fibrin and fibronectin. This fibroblasts proliferation continues with the formation of blood 
vessels, commonly known as angiogenesis [3]. Apart from the major role played by the 
fibroblast cells, epithelialization of the keratinocytes over the wound also occur during this 
phase.  
Remodeling stage begins with the advancement of the synthesis of collagen and the degradation 
of the same. Fibroblasts producing collagen crosslink it, thus increasing the wound toughness 
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accompanied by the contraction of the wounds. This takes two to three weeks or may be upto 2 
years, depending upon the type of wound. 
The wounds can be categorized into: Open and closed wounds as per the amount of exposure of 
the wounds to the environment. The wounds can also be classified as Acute and chronic wounds. 
Acute wounds are such wounds which get healed up within a time of repair whereas the chronic 
wounds are those which are hard to heal wounds and do not follow the normal physiological 
process of healing. This improper healing in chronic wounds inturn leads to chronic 
inflammations causing the development of various ulcers like diabetic foot ulcer, pressure ulcers 
and venous ulcers[4].  
Chronic wounds like those mentioned above results from various factors due to the reason that 
these factors delay the wound closure and thus the healing of the wounds. The factors affecting 
wounds include: Infections, Moisture in the wound site, Age, Stress, Obesity, disorders like 
Diabetes, non steroidal anti – inflammatory drugs, smoking and Alcohol intake. These major 
criterions decide how early or how late the wounds get healed. 
The major cause of such hard to heal wounds is: 
 Chronic Inflammation  
 Insufficient Extracellular Matrix (ECM) 
 Insufficient Angiogenesis 
 Insufficient Adipogenesis 
 Special category of ulcers. 
In wounds, the immune system responds back to cause inflammation in the body but sometimes 
like those in chronic wounds, the inflammation not only kill microbes but damage tissue as well. 
When the inflammation goes on for long durations, it causes infiltration of macrophages, 
monocytes, lymphocytes and plasma cells, instead of neutrophils. Due to the interaction of the 
inflammatory cells for a longer period of time, the tissue gets damaged by these cells [5].  
ECM plays a very important role in tissue regeneration and wound healing. It provides 
communication between the cells causing them to adhere, proliferate and differentiate over the 
surface of ECM. Insufficient ECM at the wound delays the healing process as it provides the 
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structure and adhesion to the cells and the growth factors embedded in it. Growth factors rely 
over the ECM for their activity and in the absence of ECM, the repairing process of the injured 
tissue gets disturbed [6]. Therefore the external addition of ECM can be a preferable option as in 
chronic wounds, the high level of inflammatory cells can inturn release proteases which degrade 
the ECM components and growth factors which is crucial for healing. 
Like ECM, Angiogenesis is a crucial factor in Tissue Engineering. Insufficient angiogenesis can 
cause hypoxia to occur which is unfavorable for the healing of wounds. The reason behind is 
known to be the inflammatory responses which delays the healing process due to release of 
oxygen free radicals. The overproduction of proteases from the inflammatory cells promotes the 
tissue necrosis and delays the normal healing and repair process. 
It has been recently found that the adipocytes interact or communicate with the fibroblast cells 
and repopulate during the second phase, that is, proliferative phase of the wound healing process. 
Adipogenesis is the process through which the adipocytes proliferate and migrate from the non – 
injured site to the injured one, thus increasing their population. Thus, insufficient adipogenesis 
can lead to improper proliferation and interaction of adipocytes with the fibroblasts [7]. 
Beside these causes, there are some distinct types of ulcers which come in the category of the 
chronic wounds. These include: tubercular ulcers, leishmanial ulcers, and ulcers due to the severe 
effects of cancer and AIDS. These are some of the major cause of the persisting wounds. 
Many treatments have been applied for the cure of the above mentioned problems in chronic 
wounds and in early closure and healing of the same. The use of biocompatible matrices has 
been recently produced and is used for this purpose. Some of them are Epidermal Autografts, 
Apligraf, and Dermagrafts [8-9]. Many hydrogels, foams, negative pressure topical dressings, 
and hydrocolloids are there which are recently been used [10-14]. Other than these, acellular 
matrices are also accepted for their applications in chronic wounds. These include not only 
human tissue (allograft), animal based tissue (xenograft), but also the scaffolds with collagen in 
it.  
In this study, all the five factors responsible for the chronic wounds have been dealt. For the 
study of chronic inflammation and insufficient ECM, polymer – ECM based films have been 
developed and characterized along with drug release kinetics using Curcumin which plays an 
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important role in treatment of chronic inflammation. The problem of insufficient angiogenesis is 
dealt using phytochemicals, known for their angiogenic properties through in-silico as well as 
through experimental methods. Similarly, insufficient adipogenesis is dealt through the study of 
the effect of the phytochemicals over cellular proliferation through in-silico as well as in-vitro 
analysis. The special category of ulcers was also studied using the multiple medicinal properties 
of an herbal plant Asparagus racemosus through in-silico analysis. 
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I. INSUFFICIENT EXTRACELLULAR MATRIX 
 
Chronic wounds affect millions of people exposing them to pain and reduced quality of life. 
These can be majorly due to diabetes, venous leg ulcers or application of pressure for prolonged 
period of time due to limited mobility. The progression of such wounds through normal 
physiological healing process [15] often fails due to aberrant prolongation of the inflammatory 
phase [16]. It is observed that these wounds are consequences of abnormal physiological 
conditions such as insufficient blood supply and excessive degradation of extracellular matrix 
(ECM) leading to structural and functional impairment [17] of underlying tissue and self-repair 
is generally troublesome [18]. The treatment mainly involves regeneration or replacement of 
damaged or missing tissue. Many of the researchers have found success in their attempts to 
engineer the damaged tissue [19] by using natural materials as substitutes [20-21]. Many such 
skin substitutes, that mimic human ECM, have been developed and commercialized [22]. Those 
materials have been mainly constituted of ECM derived from bovine or porcine dermal, 
submucosal or urinary bladder tissue [23-24]. The beneficial effects of these xenogenic products 
are because of their external supplementations of ECM and growth factors at the wound site. At 
the injury site, these xenogenic ECM provide structural and functional support for cells and 
binds to various growth factors, thus creating pool of active molecules and enhancing the cell 
proliferation and migration, thus mobilizing the injury during wound healing. It is also important 
to mention that the native ECM is also known to guide the immune cells. Thus, direct use of 
ECM could modulate the aberrant inflammatory phase and may play a role in better and efficient 
healing of chronic wounds [25].  
Though, omentum is known as the ‘policeman of the abdomen’ and is having very high 
proportion of ECM and growth factors, the omental ECM has never been utilized for the wound 
healing purposes. Supplementing the above facts, the greater omentum has been recently 
engaged for the isolation of ECM due to its rich vascular inventories and high level of 
angiogenic properties to support and provide higher amount of growth factors, thus enhancing 
hemostasis and preventing immune rejection of the implant [26-31].  
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It is often observed that use of only ECM as scaffold undergoes faster degradation in presence of 
proteases which are usually released by inflammatory cells in high concentration during chronic 
wounds [32-33]. For this purpose, use of biopolymer composites has gained a great importance 
[32, 34]. In this regard, chitosan deserves a special attention due its wound healing capabilities 
[35]. Chitosan is a natural polysaccharide composed of monomers β-1, 4 glucosamine (2-amino-
2-deoxy-β-D-glucose) and N-acetylglucosamine. It is considered to be very promising material 
due to its biocompatibility, biodegradability, low immunogenic and antimicrobial properties [36-
37]. As the wound bandages, chitosan itself binds with the red blood cells and initiate rapid 
clotting. In addition, it also preserves exudative wounds by restraining it from getting dried and 
contaminated, so as to promote a better condition for healing [37]. In recent years, chitosan has 
been explored extensively as wound dressings for wound healing and tissue engineering 
applications [38-40]. Chitosan has also been used to prepare hydrogels as wound dressings [41], 
gels for wound burns [42], sponge, fiber [43] as well as composite scaffolds along with collagen 
[44-45], silk fibroin and alginate dialdehyde [46], gelatin [47-49], hydroxyapatite [50], heparin 
[51] lignin [52] as well as methoxy poly(ethylene glycol) [53] to speed up the healing process.  
Alginate is a naturally existing hydrophilic polysaccharide which is generally isolated from 
seaweeds. It is a polymer of 1-4 β – D – mannuronic acid (M) and α – L – guluronic acid (G) 
monomers. Alginate is widely known for its biocompatible, biodegradable, non – antigenic and 
chelating abilities, which makes it a suitable candidate in tissue engineering and biomedical 
applications [54-55].  
Besides being non – toxic, Alginate is known to have good water absorptivity, optimal moisture 
and air transmission rate and antiseptic properties. Especially for the exudative wounds, Alginate 
based wound dressings are already in market. These include sponges, hydrogels, electrospun 
mats that enhance the gel forming as well as hemostatic ability of the dressing [56-57]. 
Alginate has also been complexed with chitosan and fibrin so as to prepare and characterize the 
composite sheets which can be used as a wound dressing. Alginate based gels are also 
recognized to promote healing by preventing the wound bed from getting dried. Recently, it was 
found that alginate based dressings can increase the healing rate by stimulating monocytes to 
release cytokines as tumor necrosis factor – α and interleukin – 6.Apart from this, the alginate 
based dressing provide an anti – microbial environment for a better wound repair and prevent 
colonization of micro – organisms that can cause infection and delay in healing [58]. 
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It is important to mention that use of ECM – Chitosan and ECM – Alginate composite may 
combine the advantageous properties of the individual components that may provide better cell 
adhesion and growth, thus enhancing the rate of tissue healing. Therefore, in the current study, 
we prepared porcine omental derived ECM – Chitosan composite films and characterized them 
for its application in chronic wound healing. 
 
1.1 MATERIALS AND METHODS 
 
Materials: 
Chitosan, Dulbecco’s Minimal Essential Media (DMEM), Dulbecco’s Phosphate Buffer Saline 
(DPBS), Trypsin-EDTA solution, Fetal Bovine Serum, Antibiotic-Antimycotic solution, MTT 
assay kit and Nutrient Broth were purchased from Himedia, Mumbai, India. Sodium Alginate 
was purchased from S.D.Fine – Chem. Ltd. The gluteraldehyde (25% aqueous solution) was 
procured from LOBA Chemie, Mumbai, India. Collagenase and Lysozyme enzyme was bought 
from MP Biomedical and Otto Chemie, Mumbai respectively. The MG63 cell line was procured 
from NCCS, Pune.  All other chemicals used were of analytical grade and were obtained locally. 
 
Methods: 
1.1.1 Decellularization and solubilization of Adipose Tissue: 
Pig omentum tissue was obtained from the slaughter house, Malegam, Rourkela under the sterile 
conditions. The tissue was washed in phosphate buffer saline (pH 7.4) thoroughly to remove any 
blood components. The double volume of phosphate buffer saline was added to the washed 
tissue and was homogenized in blender for 5 min with pulsation of 30 seconds. A thick paste of 
the homogenized tissue was then centrifuged at 8000 rpm for 10 min. The blended tissue got 
separated into three layers – supernatant, middle layer and pellet/debris. The supernatant consists 
of fat or oil due to defatting of omentum which was then discarded. After discarding the 
supernatant, the remaining was subjected to repeated freeze thawing (-21⁰C then 37⁰C). 
Thereafter, the samples were centrifuged again until no oil layer was found. The middle layer 
which is mostly tissue now consists of extracellular matrix was collected for subsequent 
processing. The tissue was then washed with distilled water, 0.2% DNase and 0.5% SDS at 37°C 
for 1 day [59]. The decellularized tissue was then solubilized in 0.5 M acetic acid solution under 
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continuous stirring for 48 hours. The solution was then filtered through muslin cloth and 
centrifuged again at 8000 rpm for 10 min to get pure ECM. The ECM was then stored at 4°C for 
further use. 
 
1.1.2. Preparation of polymer-ECM composite films: 
2% chitosan (Degree of deacetylation > 75%) solution was prepared in 0.5 M acetic acid solution 
under stirring condition. 2% alginate solution was prepared in distilled water. For which, 2gm 
sodium alginate powder was slowly added to distilled water under stirring condition. A 
homogenous solution was prepared through a continuous and overnight stirring.  On other hand, 
the ECM pellet obtained after decellularization of omentum tissue, was lyophilized to remove the 
water content from ECM pellet. Thereafter, lyophilized ECM was dissolved in 0.5M acetic acid 
solution to get a final concentration of 50 mg/ml, 100 mg/ml and 150 mg/ml. Thereafter, 
Chitosan and ECM solution (all concentrations), were mixed in 6:4 (w/w) ratio under stirring 
conditions followed by degassing. The chitosan-ECM composite films were prepared using 
Casting/ Solvent evaporation Technique as described by Maryam Koucha et al. [60]. 30 gm each 
of prepared Chitosan-ECM solutions were poured in the 90mm petri dish and dried for 48 hours 
in the vacuum oven (Q5247, Navyug, India) at 37°C. The dried composite films were removed 
from petri dish using 2N sodium hydroxide treatment for 30 minutes. Thereafter, the films were 
peeled out, washed 3-4 times with distilled water and kept for drying at 37°C for about 24 hours 
[61].  
 
1.1.3. Characterizations of polymer-ECM composite films: 
 
1.1.3.1. Thickness of the films:  
The thickness of the films was measured using digital vernier caliper (Traceable
®
 Digital 
Calipers 6in, Fischer Scientific). The thickness of each film was measured at ten different 
locations and was reported as a mean of all the measurements. 
 
1.1.3.2. Swelling Test:  
Polymer-ECM composite films of 1x1 cm
2
 were initially cross-linked using 20% gluteraldehyde 
solution for about 12 hours which were then weighed after drying (Wd). The films were then 
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immersed in phosphate buffered saline PBS (pH 7.4) ant kept at 37°C. The films were removed 
from PBS, after a regular interval of time (5, 10, 15, 30, 60, 90 and 120 min). Thereafter, excess 
of PBS was blotted off from the films using ﬁlter paper (Sartorium Stedim Biotech grade) and 
wet weight of the films (Wt) were recorded at the above mentioned time intervals [62]. The 
experiment was performed in triplicates. The % swelling was calculated which is defined as the 
ratio of the weight increase (Wt − Wd) to the initial dry weight (Wd).     
                                           Swelling ratio (%) = [(Wt – Wd) / Wd] % 
Where, 
Wt = Wet weight of films 
Wd = Dry weight of films 
 
1.1.3.3. Moisture Absorption Test:  
The films of 1x1 cm
2 
size were completely dried in the Vacuum drying oven (Labtech) for 24 hrs 
and then taken in dessicator at 84% humidity by saturated solution of KCl for 12 hours. The final 
weight of the sample films was noted. The percentage of moisture absorbed from the 
environment in the standard conditions, was calculated: 
Percentage moisture absorbed (%) =   [(Wf – Wi) / Wi] % 
Where, 
Wi = Initial weight of the films 
Wf = Weight (final) of the films after drying 
 
1.1.3.4. Water Vapor Transmission Test:  
Water vapor transmission or permeability of the Polymer-ECM composite film was evaluated 
using the water method (ASTME 96 standardized method) [63]. According to this method, the 
sample films were kept completely adhered on to the top of the cylindrical glass tubes (volume = 
71.42 cm
3
) using a Teflon tape (P.T.F.E Thread Seal Tape) (Figure 1). 
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Figure 1.  Set up for the water vapor permeability test 
 
Each tube was initially filled with pre-weighed (30 ml) PBS. The initial weight and height of the 
water (from base) was recorded and then the tubes were kept at 37°C. The readings were taken 
daily for about more than two weeks. The transmission of water vapor through the chitosan-
ECM composite films was calculated using equation: 
 
Water Vapor Transmission rate (g/day-m
2
) = [(Change in weight)/ (Time (days)] x Test 
area) 
 
1.1.3.5. Biodegradation Test:  
The films of 1x1 cm
2
 size were taken in a 12 well plate and dry weight of the films was noted. 
An enzyme cocktail of Lysozyme-Collagenase in PBS (pH 7.4) was prepared under aseptic 
conditions (1/10
th
 of total volume of Lysozyme (10,000 U/ml) - Collagenase (10 U/ml) solution 
was taken). 1 ml of prepared enzyme cocktail was added to the films under aseptic conditions 
[64] and the weight of films was recorded at definite interval of 15, 30, 60,120, 180, 240, 300, 
360,720 and 1440 min. The percentage weight loss was calculated using formula: 
% Weight loss = [(Wi – Wf)/ Wi] % 
Where, 
Wi = Initial Weight of the film, 
Wf = Final Weight of the film 
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1.1.3.6. Hemocompatibility Test:  
The hemocompatibility of polymer – ECM composite films were analyzed. The leachant 
preparation was carried out by immersing dried films (cut into 1x1 cm
2
) placed in a dialysis 
membrane in 10 ml of PBS (pH 7.4) under stirring condition of 60 rpm at 37°C for overnight. 
For Hemocompatibility studies, fresh goat blood was taken and diluted in 1:1 ratio with 0.9% 
normal saline. 0.5ml of leachant was added in blood suspension (9ml normal saline + 0.5 ml 
diluted blood) followed by the sample incubation at 37°C for 1 hour. Thereafter, the samples 
were centrifuged at 3500 rpm for 5 minutes and the supernatant was analyzed for the optical 
density at 545nm. The positive and negative controls were prepared by adding 0.1N HCl and 
normal saline respectively instead of leachant samples [65]. The percentage of haemolysis was 
measured by the following equation: 
% Haemolysis = [(Test sample – Negative Control) / (Positive Control – Negative control)] 
x 100 
 
1.1.3.7. In vitro Cytotoxicity Test:  
The biocompatibility studies were performed using MG63 cell line, procured from NCCS, Pune. 
The cell line was maintained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) with 10% Fetal 
Bovine Serum (FBS) in incubator at 37°C, 5% CO2 and 95% humidity. The cells were harvested 
using 0.25% Trypsin-EDTA solution and the viable cell density was analyzed using Trypan Blue 
dye exclusion test. Thereafter, the cells were seeded at a concentration of (1 x 10
5
) cells/ml on 
sterilized film samples. Prior to seeding of cells, the films were subjected to UV and ethanol 
sterilization. The culture plate was incubated for next 24 hours. Further, the cell viability was 
accessed using MTT Assay [66-67]. The biocompatibility studies were done in quadruplet for 
each sample and the data was reported as relative proliferation index. 
 
1.1.3.8. Fourier Transform Infrared Spectroscopy:  
The polymer – ECM composite films (including the control samples of films) were examined for 
spectroscopic analysis using FTIR spectroscopy ATR mode (Shimadzu/IR prestige 21). The 
samples were analyzed keeping air as the reference. Scanning was done at the range of 4000 cm
-1
 
to 500 cm
-1 
with a resolution of 4 cm
-1
. 
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1.1.3.9 X- Ray Diffraction:  
The X-ray diffraction pattern of polymer – ECM composite films was analyzed using X-ray 
diffractometer (PW3040, XRD-PANalytical, Philips, Holland). Cu-Kα radiation with wavelength 
0.154 nm was used as a source. The instrument was operated at 30 KV and 20mA. Scanning of 
the samples was done at 5° - 50° (2θ) with a rate of 2° (2θ) /min. The analysis was performed at 
the room temperature. 
 
1.1.4 Statistical Analysis:  
Each experiment was performed in triplicates. All the results were mentioned as the average 
(mean) ± S.D. Statistical analysis of all the quantitative data was done using one – way ANOVA 
through IBM SPSS Statistics 20.0. The results of all the samples were compared at 95% of 
confidence level. The results with p – value equal or less than 0.05 were considered to be 
statistically significant. 
 
1.2. RESULTS AND DISCUSSIONS 
  
1.2.1. Film Preparation:  
For the preparation of chitosan – ECM composite films (Figure 2), acetic acid was preferred for 
solubilization of ECM as it was found to preserve the helical structure of collagen. Thereafter, 
the films were prepared using Casting/ Solvent technique. The films were dried at 37°C for 48 
hours, thus forming thin films with sufficient mechanical strength to be used as wound healing 
bandages. 
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Figure 2.  Chitosan – Extracellular matrix and Alginate – Extracellular matrix composite films 
 
1.2.2. Characterizations of film:                                   
1.2.2.1. Film Thickness:  
The thickness becomes an important criterion of characterization for the films to be used for 
wound healing applications. It governs many of properties including water vapor permeability, 
moisture absorption, tensile strength and biodegradation. Thickness of all the polymer-ECM 
composite films was found to be significantly higher in comparison to chitosan control (Table 1) 
(p < 0.05). This could probably due to the higher ECM concentration in the composite films. 
However, it is interesting to mention that the increase in ECM concentration in the composite 
films did not contribute significantly in variations of film thickness. This may possible be due to 
insignificant difference in viscosity of ECM solution among all the three concentrations.   
 
1.2.2.2. Swelling Analysis:  
The swelling kinetics of a film is crucial determinant of its degradation kinetics and release 
kinetics. The swelling analysis reflects the affinity of the films towards water which directly 
corresponds to its hydrophilicity. For wound healing applications, hydrophilicity of the system 
determines its interaction with the tissue and aids to migrations and proliferation of cells 
subsequently leading to greater rate of wound closure. Also for exudative wounds, the films with 
better absorbing capacity are required which help in keeping the wound bed moist and exudate 
free. In our study, the swelling of the chitosan-ECM composite films as well as the alginate – 
ECM composite films were found to be significantly higher in comparison to chitosan as well as 
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alginate control (p < 0.05) (Figure 3, Table 1). It was observed that the increase in ECM 
concentration increased the water retention capability of the composite films. This could possibly 
due to increase in hydrophilicity of the composite films with the addition of ECM. However, an 
insignificant difference in swelling was observed between CE100 and CE150. This may be due 
to higher interaction between ECM fibers or ECM-chitosan backbone, which may restrict the 
number of free functional groups available to interact with water molecules. Similarly for 
alginate, there is a significant difference between the alginate control and the one with ECM.  
 
 
Figure 3. Swelling test of Chitosan – Extracellular matrix and Alginate – Extracellular matrix 
composite films 
 
Table 1: Thickness, Percentage Swelling and Moisture absorption of ECM – Chitosan film 
samples 
 
 
 
 
 
SAMPLE 
Thickness  ± 
Std Dev (mm) 
% Swelling ± 
Std Dev (%) 
% Moisture 
Absorbed (± 
Std Dev) 
Chitosan Control (CC) 0.050 ± 0.01 20.325 ± 0.94 14.080 ± 1.03 
Chitosan – ECM (50 mg/ ml) 
(CE50) 
0.080 ± 0.01 31.826 ± 1.14 15.738 ± 2.18 
Chitosan – ECM (100 mg/ ml) 
(CE100) 
0.089 ± 0.01 47.198 ± 1.25 25.579 ± 1.82 
Chitosan – ECM (150 mg/ ml) 
(CE150) 
0.090 ± 0.01 48.464 ± 1.08  28.086 ± 2.26 
15 
 
Table 2: Thickness, Percentage Swelling and Moisture absorption of ECM – Alginate film 
samples 
 
 
 
 
 
 
 
 
 
 
 
1.2.2.3. Moisture Absorption Test:  
Moisture absorption test is carried out to analyze the ability of the films to absorb moisture from 
the environment. It is generally seen that the presence of moisture accelerates the wound healing 
process. Thus, it becomes an essential selection criterion for selection of films suitable for wound 
healing applications. Both chitosan-ECM and alginate – ECM composite films demonstrated a 
higher degree of moisture absorption in comparison to chitosan and alginate control respectively 
(p < 0.05), under standard conditions of saturated solution of KCl. It is important to mention that 
with an increase in ECM concentration in the formulation, the moisture absorption ability of the 
films also increased (Table 1). However, increase in ECM concentration, results into low 
porosity of the films but increases the hydrophilicity drastically which may aid to better moisture 
absorption ability of CE150 in comparison to rest of the formulations. Similarly, decrease in 
porosity and increase in compactness results into lower chances of evaporation of absorbed 
moisture back into the environment.  
 
1.2.2.4. Water Vapor Transmission Test:  
According to the standards of ASTME, water vapor transmission rate or water vapor 
permeability refers to the flow of water vapor per unit time through a unit area of the body, under 
specific conditions of humidity and temperature. It is important to mention that the loss of water 
SAMPLE 
Thickness  ± 
Std Dev (mm) 
% Swelling ± 
Std Dev (%) 
% Moisture 
Absorbed (± 
Std Dev) 
Alginate Control (AC) 0.061 ± 0.01 51.196 ± 0.94 15.749 ± 0.50 
Alginate – ECM (50 mg/ ml) 
(AE50) 
0.075 ± 0.01 80.729 ± 0.94 38.782 ± 1.31 
Alginate – ECM (100 mg/ ml) 
(AE100) 
0.078 ± 0.01 86.141 ± 0.94 42.631 ± 1.07 
Alginate – ECM (150 mg/ ml) 
(AE150) 
0.080 ± 0.01 91.403 ± 0.94 44.067 ± 2.02 
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vapour from the intact skin is 240-1920g/m
2
/24 hours, while it rises to 4800g/m
2
/24 hours in case 
of open wound [68]. As discussed above, wound healing is faster in the presence of moisture 
than in case of dry environment. Thus, ability of film to permeate water vapour becomes an 
essential criterion for their selection. The films may find variable applications depending upon 
their water permeability. A film with low water permeability could be effectively be used in low 
exudative wounds while a film with high water vapour permeability could be used for high 
exudative wounds. For polymer-ECM composite films, water vapour permeability test was 
carried out as per the protocol described in [63] and the data was recorded for 16 days. The 
variation in the water vapor transmission rate was found as statistically significant between the 
composites and control films (p < 0.05) (Table 3 and Table 4). In a wider view, as the ECM 
concentration was increasing, the transmission of water vapor was found to be decreasing. This 
can be due to the fact that ECM being hydrophilic and binds water molecule. Also, increase in 
ECM concentration decreases the porosity of films which may contribute to lower water vapour 
transmission. 
 
Table 3: Water vapor transmission rate and percentage hemolysis of the Chitosan – ECM 
composite films 
 
 
 
 
 
 
 
 
 
Table 4: Water vapor transmission rate and percentage hemolysis of the Alginate – ECM 
composite films 
SAMPLE 
Water Vapor 
transmission rate ± 
Std Dev (g/day.m
2
)  
% Hemolysis ± 
Std Dev (%) 
Chitosan Control (CC) 2.799 ± 1.20 3.514± 0.14 
Chitosan – ECM (50 mg/ ml) 
(CE50) 
2.539 ± 0.58 2.882±0.26 
Chitosan – ECM (100 mg/ ml) 
(CE100) 
2.401 ± 0.26 2.792±0.87 
Chitosan – ECM (150 mg/ ml) 
(CE150) 
2.349 ± 1.19 2.072±0.48 
SAMPLE 
Water Vapor 
transmission rate ± 
Std Dev (g/day.m
2
)  
% Hemolysis ± 
Std Dev (%) 
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1.2.2.5 Biodegradation Study:  
The degradation profile of the films/bandages to be used for wound healing is of great 
importance. Once the films are applied onto the wound, they come in contact with variety of 
enzymes including Matrix Metalloproteinase’s. It is also important to mention that, apart from 
enzymes from human source; the enzymes from microbes present in the environment also 
interact with the matrix and degrade it. Thus, it is important to characterize the degradation 
profile of the films before use. In our analysis, films were treated with Lysozyme-Collagenase 
solution in PBS with lysozyme and collagenase in concentration of 10,000 U/ml and 10 U/ml 
respectively, and the weight of the film sample was weighed at regular interval (Figure 4). 
Initially, the weight of the sample increased, due to the dilation in the samples due to the 
swelling. The differences in the degradation profile of the formulated films were found to be 
insignificant. 
 
Figure 4. Biodegradability Test of Chitosan – Extracellular matrix composite films 
 
Alginate Control (AC) 3.821 ± 0.46 1.930 ± 0.24 
Alginate  – ECM (50 mg/ ml) 
(AE50) 
3.529 ± 0.63 1.124 ± 0.99 
Alginate  – ECM (100 mg/ ml) 
(AE100) 
3.103 ± 0.92 0.414 ± 0.83 
Alginate  – ECM (150 mg/ ml) 
(AE150) 
2.898 ± 1.23 0.011 ± 0.75 
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The Alginate – ECM composite films got disintegrated within an hour. This may be due to the 
reason that the films were not crosslinked. The swelling that was observed in the biodegradation 
study was not upto the extent as observed in the swelling study because of the simultaneous 
biodegradation of the films in the presence of the enzymes. This was supported with the further 
fact that the control samples which were taken only in PBS, the increase in weight continued 
upto 2 hours, before decrease in the weight starts because of disintegration and degradation.  
 
1.2.2.6. Hemocompatibility Test:   
Hemocompatibility assay is one the essential criteria in analyzing the compatibility of the 
polymer blends.  Autian suggested that the hemocompatibility of the polymer depends on the 
extent of hemolysis. Percentage hemolysis less than 5% indicate high degree of 
hemocompatibility, whereas equal or more than 5% indicate moderate or least 
hemocompatibility, respectively. The results obtained were also less than 5% for all the samples 
(Table 3 and 4) which is within the acceptable range established by Autian, similarly found by 
XH Qu et al. [69-70]. All the samples were found to shown compatibility with the blood. It was 
interesting to observe a decrement in the % hemolysis with the increase in the concentration of 
extracellular matrix. There was no significant difference between the samples, yet it was 
considerably lower than the positive control which showed 100 % hemolysis. The degree of 
hemolysis, when compared among all the samples, were found to be statistically significant with 
p= 0.05. 
 
1.2.2.7. In vitro Cytotoxicity Test:  
The biocompatibility/cytotoxicity of the chitosan-ECM composite films was analyzed using the 
MTT assay that measures the activity of Mitochondrial Succinate Dehyrdogenase enzyme. The 
general observation is that the activity of the enzyme corresponds to the number of viable cells 
present. The degree of biocompatibility was expressed as the relative proliferation of the MG63 
cells when exposed to films of each blend. This can be viewed in the graphical interpretation as 
seen in Figure 5. The biocompatibility assay of the polymeric blends showed that the cell 
proliferation index in all the sets were under acceptable ranges. An increase in the 
biocompatibility was observed with the increase in ECM concentration in the blended films.  
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Figure 5. In vitro Cytotoxicity test of Chitosan – Extracellular matrix and Alginate – 
Extracellular matrix composite films 
 
 
1.2.2.8. Fourier Transform Infrared Spectroscopy:   
FTIR analysis was done to see the organic constituent present in the chitosan - ECM films as 
well as the alginate – ECM films. The graphical interpretation can be seen in Figure 6. Through 
FTIR, the peaks of amide I, amide II, amide III, CH, CH2, CH3, NH, C-O, COO
-
, C-N, N-H, and 
C=O and cross linked C=O functional groups were analyzed. Wave numbers (cm
-1
) of different 
functional groups present in Chitosan [71] are given in Table 5, whereas those of functional 
groups present in collagen, the major component of ECM [72] are tabulated in Table 6. 
 
Table 5: Wave number of different functional groups present in Chitosan 
S.NO FUNCTIONAL GROUPS WAVENUMBER (cm
-1
) 
1 N–H and O–H stretching vibration 3439 cm-1 
2 CH3 symmetric stretch 2925 cm
-1
 
3 C=O stretching vibration 1666 cm
-1
 
4 C–N stretching vibration 1438 cm-1 
5 CH3 bending vibration 1363 cm
-1 
6 C–O–C bending vibration 1155 cm-1 
7 C–OH stretching vibration 1073 cm-1 
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The Chitosan ECM film samples, when tested through FTIR, showed somewhat similar peaks of 
chitosan at 3428 cm
-1
 (N-H and O-H stretching bonds), 2949 cm
-1
(CH3 symmetric stretch), 1663 
cm
-1
 (C=O stretching vibration), 1439 cm
-1
 (C–N stretching vibration), 1365 cm-1 (CH3 bending 
vibration), 1134 cm
-1
 (C–O–C bending vibration), and 1084 cm-1 (C–OH stretching vibration).  
 
Table 6: Wave number of different functional groups present in Alginate 
S.NO. FUNCTIONAL GROUPS WAVENUMBER(cm
-1
) 
1 OH− stretching 3242 cm−1 
2 COO
-
 asymmetric stretching 1596 cm 
-1 
3 COO
-
 symmetric stretching 1407 cm
−1
 
4 C-O-C anti-symmetric stretching 1081-1024 cm
−1
 
5 carboxyl and carboxylate 1000 to 1400 cm
−1
 
 
Table 7: Wave number of different functional groups present in ECM 
S.NO. FUNCTIONAL GROUPS WAVENUMBER(cm
-1
) 
1 Amide I region; mainly C=O, C-N bonds 1700-1600 
2 Amide II region; mainly combination of C-
N stretching and N-H bending vibrations 
1600- 1585 
3 CH2 bending vibrations, CH3 asymmetric 
bending vibrations, COO
-
 stretching 
vibrations, and CH2 side chains of collagen 
1500 – 1300 
4 CH2 side chains vibration 1340 
5 Amide III region; mainly C-N stretching, 
N-H bending, C-C stretching, and sulfate 
stretching vibrations 
1300 – 1180 
6 Carbohydrate region: stretching vibrations 
of C-O, C-O-C, C-OH as well as C-C ring 
vibrations 
1100-1005 
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Moreover, the presence of ECM was confirmed at 1622 cm
-1
, 1630 cm
-1
, 1638 cm
-1
, and  1644 
cm
-1
 (Amide I bands); 1552 cm
-1
, 1560 cm
-1
, and 1579 cm
-1
 (Amide II bands); 1259 cm
-1 
(Amide 
III bands); 1329 cm
-1
, 1382 cm
-1
, 1414 cm
-1
, and 1417 cm
-1
 (CH2 bending vibrations, CH3 
asymmetric bending vibrations, COO
-
 stretching vibrations, and CH2 side chains of collagen); 
990 cm
-1 
and 1121 cm
-1
 (Carbohydrate region: Stretching vibrations of C-O and C-OH as well as 
C-C ring vibrations).  
  
                                           (A)                                                              (B) 
Figure 6. FTIR peak analysis of Chitosan – Extracellular matrix and Alginate – Extracelluar 
matrix composite films 
 
 
1.2.2.9 X - Ray Diffraction:  
Figure 7 shows the X- ray diffraction pattern of polymer – ECM films. X’Pert Highscore 
(Version 1.0b, Philips analytical B.V) was used to analyze the diffractograms of the film 
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samples. According to the literature, the peaks of pure chitosan are generally found near 10° and 
20° 2θ [73]. For pure collagen which is a major constituent of ECM, there is a broad diffraction 
pattern at 10° 2θ and a characteristic peak at 23° 2θ [74]. The typical peaks of chitosan in the 
chitosan – ECM films were found to be at 11.7° and 26.8° 2θ. Similarly, XRD analysis showed 
that sodium alginate exhibited a very small crystallinity with peaks at 12°, 23.1°, 31.3°, and 
43.8°. Moreover, the presence of ECM in the films was confirmed by the characteristic peaks 
observed at 22.8°, 26° and 29.16° 2θ with 50mg/ml, 100mg/ml and 150mg/ml ECM 
concentration respectively. On comparing the diffractograms, it can be observed that as the ECM 
is introduced in chitosan, there is a strong peak formation, which gets broaden as the ECM 
increases. This relates to the increase in the amorphous nature of the film. Shift and the 
broadness of the peak denote that there is certain decrease in the crystallinity.  
 
  
                                              (A)                                                       (B) 
Figure 7.  Analysis of XRD pattern in (A) Chitosan – Extracellular matrix and (B) Alginate – 
Extracellular matrix composite films 
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4. CONCLUSION 
The current study was done to prepare the composite films of Chitosan/ Alginate – porcine 
omental derived ECM hypothesizing the additive advantages of both for the application in 
chronic wound healing. The addition of ECM in the chitosan as well as alginate increases the 
hydrophilicity, hemocompatibility and biocompatibility which have an added advantage over 
management of chronic wounds. In future, the comparison of the characteristics between the 
lyophilized and the dried composite films will be made and furthermore immunogenicity of the 
films will be tested in vivo. 
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II. INSUFFICIENT ANGIOGENESIS 
 
Angiogenesis is a complex and intricate process wherein the pre-existing blood vessels and 
capillaries give rise to the new ones [75-76]. These blood vessels distribute the nutrients; carry 
out gas exchange and transport waste, thus maintaining a balanced healthy environment 
throughout the tissue [77]. Optimally regulated angiogenesis is very essential for proper growth 
and development of tissue. On the other hand, a deregulated angiogenesis leads to various 
diseases such as cancer, obesity, diabetes, arthritis, uterine bleedings, Alzheimer’s, osteoporosis, 
stroke, atherosclerosis etc. There exist various chemical mediators like Vascular Endothelial 
Growth Factors (VEGF), Fibroblast Growth Factor (FGF), Epidermal Growth Factor (EGF), 
angiostatin, interferon etc. which regulate the angiogenic process [78]. Amongst all such 
mediators, VEGF is the most prominent inducer of angiogenesis. VEGF is essential for the 
migration, proliferation and formation of capillary like structures by endothelial cells. VEGF 
executes its actions by binding to its receptors (VEGFR1 and VEGFR2) on the endothelial cells, 
thus activating the cascade of many downstream signaling pathways essential for 
angiogenesis[79]. Chemicals that interrupt this signaling cascade act as angiogenesis inhibitors. 
Angiogenic inhibitors have potential therapeutic utility in cancer, age related macular 
degeneration and other diseases where vascular proliferation leads to pathogenesis. Recently, a 
number of plant derived natural compounds or phytochemicals have been reported to possess a 
potential anti-angiogenic activity[80-81]. Schindler et al and Bagli et al reported that the 
flavonoids like genistein and luteolin have a profound inhibitory effect on VEGF secretion in the 
cancer cells, thus inhibiting the tumor growth[82-83]. Also, curcumin has been reported for its 
anti-angiogenic potentials through down-regulation of VEGF expression and inhibition of 
VEGFRs[84]. 
Some medicinal plants such as, Pueraria tuberosa (Vidarikanda), Asparagus racemosus 
(Shatavari), and Ficus bengalensis (Bargad) are historically known to show wide variety of roles 
in medicinal field. In the current study, we have tried to follow an in silico approach to evaluate 
the effect of various phytochemicals over the Vascular Endothelial Growth Factor Receptors 
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(VEGFRs). These tyrosine kinase receptors have an extracellular as well as the intracellular 
domain. The critical protein models of VEGFR1 and VEGFR2 encoding for both the 
extracellular domain and intracellular domain have been isolated computationally and were 
docked with the non – toxic phytochemicals obtained from the above mentioned medicinal 
plants. 
Pueraria tuberosa or Indian Kudzu is widely known in traditional medicines to have many 
medicinal benefits. It has exhibited cardiotonic, aphrodisiac, anti-hyperglycemic, anti-lipidemic 
and galactogogue activities [85-88]. Tubers of Pueraria tuberosa are rich in Daidzin, Puerarin, 
Puerarone, genistein, Puetuberosanol, Tuberostan, Tuberosin, and Puerarin 4',6''-diacetate [89-
91].Though it has many health beneficial effect but its effect on angiogenesis not been studied 
much. 
Asparagus racemosus, a member of Asparagaceae family is also known as Shatavari. This is one 
of the endangered species which has been reported to retain the ability to treat number of 
diseases and disorders. The  extracts from various parts of this aryuvedic plant is well known to 
possess anti-ulcer, anti-bacterial, anti-depressant, anti-inflammatory antiprotozoal, antiviral, 
antioxidant and antitumorigenic properties [92]. 
Another plant, Ficus benghalensis is an evergreen tree which is distributed all over India. This 
plant has not only antioxidant properties, but also antitumorigenic, antihelmintic, anti-
inflammatory, anti allergic, anti diabetic, analgesic. This plant has also been evaluated for its 
wound curing abilities as well [93-94]. 
In the current investigation, we have tried to evaluate the effect of various phytochemicals 
derived from aforesaid plant source on the Vascular Endothelial Growth Factor Receptors 
(VEGFRs) using in silico approach. The phytochemicals were screened for their toxic and 
mutagenic effects. Further, the nontoxic and non-mutagenic phytochemicals were docked onto 
kinase domain of VEGFR1 and VEGFR2. 
 
2.1. MATERIALS AND METHODS 
2.1.1. Protein structure retrieval& Active site predictions: 
The three dimensional structural models of intracellular kinase domain of VEGFR1 & VEGFR2 
proteins were deduced from RCSB Protein Data Bank (http://www.rcsb.org). The cleaning and 
optimization of the protein model geometry was carried out by removal of miscellaneous ligands 
26 
 
and other hetero-atoms such as water, ions etc. using Argus Lab Software. Further, the protein 
models were used for the active site prediction using CASTp Calculations (Computed Atlas of 
Surface Topography of proteins) (http://stsfw.bioengr.uic.edu/castp/calculation.php). Amongst 
all predicted sites, the site having the catalytic amino acids was selected for docking. The clue 
about the amino acids involved in protein catalysis was gained from UniProt Server 
(http://www.uniprot.org/). 
 
2.1.2. Substrate selection: 
The three dimensional PDB structures of the phytochemicals present in the aforesaid plants and 
the standard FDA approved drug molecules were retrieved from KNApSAcK-3D 
(http://knapsack3d.sakura.ne.jp/) and PubChem (http://pubchem.ncbi.nlm.nih.gov/) databases 
using PRODRG Server (http://davapc1.bioch.dundee.ac.uk/prodrg/). Further, energy 
minimization & ligand optimization was carried out using Argus lab software. 
 
2.1.3. Molecular Property Predictions: 
The selected phytochemicals were examined for their molecular properties, ADME and toxicity 
using PreADMET (http://preadmet.bmdrc.org/).The phytochemicals which passed the selection 
criterion were used for the docking analysis. 
 
2.1.4. Molecular Docking: 
The selected phytochemicals were docked into the active sites of the protein models using 
AutoDock4.2 software tool. In brief, polar hydrogen and Kollman charges were added to the 
protein models and docking was done by Lamarckian Genetic Algorithm using standard protocol 
based on the population size of 150 haphazardly located individuals; a maximum number of 
2.5*10
7
 energy evaluations, with 0.02 mutation rate and 0.8 crossover rate [95]. Twenty 
independent docking runs were carried out and results were clustered according to the 1.0 Ǻ 
RMSD criteria. Auto gridding was done in the grid maps of proteins, setting the grid size of 
60*60*60 points along with grid spacing of 0.375 Ǻ. This was followed by the visualization of 
the interaction details in the protein-ligand complex using UCSF chimera [96] and LigPlot
+ 
[97]. 
 
2.1.5. Extraction of the Phytochemicals: 
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Asparagus racemosus and Ficus benghalensis were selected for the extraction of the 
phytochemicals due to the availability of these plants. The plants were washed thoroughly two to 
three times. The required portion of the plant was taken and cut into tiny pieces which were 
made into powder using liquid N2. The powder was loaded in the thimble paper and placed in the 
porous container of the soxhlet apparatus. Complete set up was prepared and started. The extract 
gets filtered and gets collected in the distilled pot which is collected. The extract is dried using a 
vacuum evaporator and was stored in dark at 4°C. The extract having the phytochemicals were 
tested for their presence through the biochemical analysis. The Phytochemical screening was 
carried out by the method of Harborne, 1973. A stock solution of concentration 1 mg/ml was 
used as the extract for the phytochemical analysis [98-99].  
  
 Test for carbohydrates:  
To 2 ml of extract, 1 ml of Molisch’s reagent and few drops of concentrated hydrochloric acid 
were added. The appearance of reddish colour indicates the presence of carbohydrates.  
  
 Test for tannins:  
For testing the presence of tannins, 2 ml of 5 % ferric chloride was added to 1 ml of the plant 
extract. The appearance of dark blue or greenish blue colour showed the presence of tannins.  
  
 Test for saponins:  
The presence of saponins was confirmed by adding 2 ml of distilled water to 2 ml of plant 
extract, followed by shaking in a graduated cylinder for about 15 minutes. There is a formation 
of about 1 cm layer of foam indicates the presence of saponins.  
  
 Test for flavonoids:  
The appearance of yellow colour indicated the presence of flavonoids when 1 ml of 2N sodium 
hydroxide was added to 2 ml of the plant extract. 
  
 Test for alkaloids:  
To 2 ml of extract, 2 ml of Wagner’s reagent were added. The appearance of reddish brown 
colour precipitate confirms the presence of alkaloids.  
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 Test for quinines:  
To 1 ml of extract, 1ml of concentrated sulphuric acid was added. The appearance of red color 
indicates the presence of quinones.  
 
 Test for steroids: 
Test for steroids included the addition of 1 ml of chloroform and few drops of concentrated 
hydrochloric acid to 1 ml of extract. The formation of brown ring at the interface confirms the 
presence of steroids. 
 
 Test for terpenoids:  
To 0.5 ml of extract, 2 ml of chloroform and few drops of concentrated hydrochloric acid were 
added. The formation of red brown color at the interface indicates the presence of terpenoids.  
 
2.1.6. Cell Proliferation Assay: 
The phytochemicals which were came out to be the better ones, were chosen for the in vitro analysis. 
Cell proliferation assay was done to check the effects of these phytochemicals. These were taken in 
two sets- one of higher concentrations and the other, the lower ones. 96 well plates were seeded 
which were loaded with the concentrations of the drug or phytochemical after 24 hrs. MTT assay was 
done from 0
th
 day to 4
th
 day. The absorbance of all the samples was taken and relative proliferation 
index was calculated.  
 
2.2. RESULTS & DISCUSSIONS 
2.2.1. In silico analysis: 
VEGFR1 and VEGFR2 are the transmembrane tyrosine kinase receptors with all the three 
domains: extracellular domain, transmembrane region, and an intracellular domain. Although 
VEGFR1 was earlier considered as a negative regulator of VEGFR2, but recently it was also 
found to cause the accumulation of the angioblast cells in the blood vessels. On the other hand, 
VEGFR2 plays a primary role in angiogenesis, vascular permeability and differentiation of the 
above mentioned angioblast cells [100].  
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Usually, the FDA approved anti-angiogenic drugs are targeted at the intracellular domain of the 
VEGFRs, including the ATP binding domain. ATP binding domain gains a special attention 
while considering receptor tyrosine kinases as ATP hydrolysis plays a crucial role in their 
activation. Thus, inhibition of this domain may potentially inhibit the signaling pathways. 
Keeping this prospective in mind, we evaluated the inhibitory potentials of phytochemicals by 
blocking the ATP binding domain of VEGFRs. Recently, interaction between juxtamembrane 
domain and catalytic domain of VEGFR2 has gained a significant attention. Juxtamembrane 
domain connects the transmembrane domain with the catalytic intracellular domain in receptor 
tyrosine kinases [101]. James Solowiej et al have reported that the presence of the 
Juxtamembrane domain of VEGFR2 has a substantial effect on inhibitor binding to the catalytic 
domain of VEGFR2. It was observed that presence of juxtamembrane domain enhanced the 
affinity of Axitinib for the catalytic domain of VEGFR2 [102]. However, absence of an intact X-
Ray crystallographic structure for the same, limits it use for the present in silico investigation. 
Thus, three dimensional structures of catalytic domain of VEGFR1 (3HNG) and VEGFR2 
(3VHE) were taken for the analysis from RSCB PDB (Table 8). For in silico analysis of the 
ligand-protein interaction, the knowledge of active site of the protein is essential because ligands 
usually target the active sites. The active site of proteins was predicted using CASTp 
Calculations. 
 
Table 8: Targets to check the effect on Angiogenesis 
Proteins Notations PDB ID Organism Ref. 
Vascular Endothelial 
Growth Factor Receptor 
1 
VEGFR1 3HNG Homo Sapiens [103] 
Vascular Endothelial 
Growth Factor Receptor 
2  
VEGFR2 3VHE Homo Sapiens [104] 
 
The three dimensional structure of phytochemicals was isolated from KNApSacK-3D & 
PubChem database. Screening of the phytochemicals was carried out using PreADMET server 
and was based on their molecular properties including drug likeness, carcinogenicity and 
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mutagenicity. The ligands which passed the selection criteria were further subjected to docking 
analysis. Eighteen out of one hundred forty molecules were found to be non-toxic and were used 
for docking study using AutoDock4.2. Non-toxic eighteen molecules were docked with the 
intracellular domain of VEGFRs, within which Puerarone and Tuberostan gave best binding with 
VEGFR1 and VEGFR2. Further study was continued with these two molecules. The origin and 
chemical structures of these molecules is mentioned in Table 9. 
 
Table 9: Name and the origin of the selected phytochemicals 
 
KNApSAcK 
ID 
Name of the 
Phytochemical 
Origin Ref 
C00009871 Puerarone 
Pueraria tuberosa 
(Vidarikanda) 
[105] 
C00010049 Tuberostan 
Pueraria tuberosa 
(Vidarikanda) 
[106] 
C00034434 Asparagamine A 
Asparagus racemosus 
(Shatavari) 
[107] 
44257152 
Leucopelargonidin 
3 - O - glucoside 
 Ficus bengalensis (Bargad) [108] 
 
Puerarone and Tuberostan, both were found to follow Lipinski’s rule of five which permit the 
assessment of pharmacokinetics of the drug including absorption, distribution, metabolism and 
excretion (ADME). Furthermore, they were recognized as non-toxic, non-mutagenic and non-
carcinogenic in nature (Table 10). 
 
Table 10: Molecular properties of the selected phytochemicals 
PROPERTIES Puerarone 
Asparagamine 
A 
Tuberostan LPGG 
Molecular weight 
(gm/mol) 
336.33804  385.45 348.34874 452.40866 
Log P 5.09 2.24 5.87 -1.97 
HB donor 2 1 0 8 
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HB acceptors 5 6 5 11 
AMES Test 
Non 
Mutagen 
Non Mutagen 
Non 
Mutagen 
Non 
Mutagen 
Carcinogenicity 
Non 
Carcinogen 
Non 
Carcinogen 
Non 
Carcinogen 
Non 
Carcinogen 
Human Intestinal 
Absorption (%) 
93.881 90.947 95.894 14.96 
In Vitro Plasma Protein 
Binding (%) 
94.938 44.936 89.858 67.229 
 
Puerarone (KNApSAcK_3D ID C00009871) displayed best affinity towards the intracellular 
domain of VEGFR1 with binding energy of -9.91 kcal/mol (Ki: 0.182 µM). On the other hand, 
Tuberostan (KNApSAcK_3D ID C00010049) showed highest affinity towards the intracellular 
domain of VEGFR2 with binding energy of -9.32 kcal/mol (Ki: 0.148 µM). When compared 
with all the FDA approved drugs as mentioned in the table , it was found that Puerarone showed 
better binding affinity with VEGFR1 intracellular domain with the exception of Pazopanib and 
Vatalanib where it showed comparable results. Similarly, Tuberostan showed better results than 
all the drugs except Pazopanib and Axitinib where it showed almost equal results. In table 11, 
red colored values represents best affinity of the test molecules with the intracellular domain of 
VEGFR1 and VEGFR2. 
As per Asparagamine A (KNApSAcK_3D ID C00034434) is concerned, it showed binding of -
8.74kcal/mol (Ki: 0.194). Similarly, Leucopelargonidin 3-o-glucoside (LPGG) showed binding 
affinity of -7.36kcal/mol (Ki: 2). In VEGFR2, Asparagamine A and LPGG showed binding of -
8.24 (Ki: 0.456) and -7.7 kcal/mol (Ki: 1.13). 
 
Table 11: Binding interaction of VEGFR1 and VEGFR2 with selected phytochemicals. 
PDB 
ID 
Ligands 
Minimum 
Binding 
Energy 
(kcal/mol) 
Ki 
(µM) 
Hydrogen 
Bonds 
Interacting Amino 
Acids 
VEGFR1 
3HNG Test 
molecule 
Puerarone -9.91 0.182 0 - 
Tuberostan -8.44 0.646 0 - 
 Asparagamine  -8.74 0.194 0  - 
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A 
 
Leucopelargon
idin 3-o- 
glucoside 
-7.36 2 6 
Asp807, Glu878, 
Cys1018, Asp1040, 
Leu1043 
Standard 
Inhibitors 
Sunitinib -7.44 7.0 3 Cys912 (2), Cys1039 
Pazopanib -10.19 0.034 
3 
Lys861, His1020, 
Asp1040 
Axitinib -9.86 0.059 
3 
Cys1018, Asp1040 
(2) 
Vandetanib -8.54 0.5493 0 - 
Vatalanib -12.18 0.0018 
3 
Glu878, Cys912, 
Asp1040 
Sorafenib -9.44 0.120 3 Cys912(2), Asp1040 
VEGFR2 
3VHE Test 
molecule 
Puerarone -7.91 1.58 1 Cys1045 
Tuberostan -9.32 0.148 0 - 
 
Asparagamine 
A 
-8.24 0.456 1 Asp1046 
 
Leucopelargon
idin 3-o-
glucoside 
-7.7 1.13 5 
Asp814, Cys817, 
Ala881 
Standard 
Inhibitors 
Sunitinib -6.26 51.98 4 Asp814, Lys868, Ala 
881, Leu1049 
Pazopanib -9.58 0.095 1 Asp1046 
Axitinib -9.94 0.052 1 Lys868 
Vandetanib -7.36 4.01 0 - 
Vatalanib -8.78 0.367 1 Asp1046 
Sorafenib -7.7 2.26 1 Lys868 
 
For an effective binding of a ligand with a protein receptor, the affinity of the ligand towards the 
protein as well as the stability of the protein ligand complex, are some of the important 
benchmarks. The above mentioned binding energies along with the interaction profile (hydrogen 
bonds & hydrophobic interactions) provide an important indication for the affinity and stability 
of ligand with the protein. The hydrogen bonds and hydrophobic interactions formed between 
proteins and phytochemicals were illustrated through LigPlot
+ 
(Table 12). Interaction profiles 
were figured out only for the best possible orientation of the selected ligand molecule. For 
LigPlot+ analysis, an illustrative figure was generated for each ligand, describing bonded as well 
as non – bonded interactions between the ligands and protein.  
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Table 12: Binding interaction of VEGFR1 and VEGFR2 extracellular domain with selected 
phytochemicals. 
PDB ID Ligands 
Hydrogen 
Bonds 
Hydrophobic Interactions 
VEGFR1 
3HNG Test 
molecules 
Puerarone Glu878, 
Glu910 
Leu833, Val841, Ala859, 
Lys861,Leu882, Val892, Val907, 
Val909, Tyr911, Cys912, Gly915, 
Leu1029, Cys1039, Phe1041 
 Tuberostan - Leu833, Val841, Ala859, Lys861, 
Glu878, Ile881, Leu882, Ile885, 
Val892, Val907, Val909, Cys1018, 
Leu1029, Ile1038, Cys1039, Asp1040 
 
Asparagamine A Asp1040 
Ala874, Thr877, Glu878, Ile881, 
Leu882, Val892, Cys1018, His1020, 
Ile1038, Cys1039, Gly1042 
 
LPGG 
Asp807, 
Glu878, 
Asp1040 
Thr877, Ile881, Ile885, Leu1013, 
Cys1018, Gly1042, Leu1043 
Standard 
Inhibitors 
Sunitinib Cys912 (2), 
Cys1039 
Leu833, Val841, Ala859, Glu878, 
Leu882, Val907, Val909, Glu910, 
Tyr911, Gly915, Asn916, Leu1029, 
Asp1040, Phe1041 
Pazopanib Asp1040 Leu833, Val841, Lys861, Glu878, 
Val892, Val909, Tyr911, Cys912, 
His1020, Leu1029, Cys1039, Phe1041 
Axitinib Asp1040 (3) Asp807, Lys861, Glu878, Ile881, 
Leu882, Vaal892, Cys1018, Ile1019, 
His1020, Arg1021, Ile1038, Cys1039 
Vandetanib - Val841, Glu878, Ile881, Leu882, 
Ile885, Val891, Val892, Val909, 
Leu1013, Leu1029, Ile1038, Cys1039, 
Asp1040, Phe1041 
Vatalanib Glu878, 
Cys912, 
Asp1040 (2) 
Leu833, Ala859, Lys861, Leu882, 
Val891, Val907, Val909, Glu910, 
Tyr911, Leu1013, Leu1029, Ile1038, 
Cys1039, Phe1041 
Sorafenib Cys912, 
Asp1040 
Leu833, Val841, Ala859, Lys861, 
Glu878, Ile881, Leu882, Val892, 
Val909, Glu910, Tyr911, Gly915, 
Leu1013, Cy1018, Cys1039 
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VEGFR2 
3VHE Test 
molecules 
Puerarone Glu885, 
Cys1045 
Leu840, Val848, Ala866, Lys868, 
Lue889, Val916, Gly922, Asn923, 
Lue1035, Asp1046, Phe1047 
Tuberostan - Lue840, Val848,  Lys868, Glu885, 
Leu889, Val899, Val916, Phe918, 
Cys919, Lys920, Gly922, Cys1045, 
Asp1046, Phe1047 
 
Asparagamine A Asp1040 
Ala874, Thr877, Glu878, Ile881, 
Leu882, Val892, Cys1018, His1020, 
Ile1038, Cys1039, Gly1042 
 
Leucopelargonidin 
3-o-glucoside 
Asp807, 
Glu878, 
Asp1040 
Thr877, Ile881, Ile885, Leu1013, 
Cys1018, Gly1042, Leu1043 
Standard 
Inhibitors 
Sunitinib Asp814, 
Lys868, Ala 
881, Leu1049 
Cys817, Leu882, Ser884, Glu885, 
Ile888, Asp1046, Gly1048 
Pazopanib Asp1046 Val848, Ala866, Val867, Lys868, 
Glu885, Ile888, Leu889, Val899, 
Val914, Val916, Cys919, Gly922, 
Leu1035, Cys1045, Phe1047 
Axitinib Asp1046 Leu840, Val848, Ala866, Lys868, 
Glu885, Leu889, Val899, Val916, 
Phe918, Cys919, Gly922, Leu1035, 
Cys1045, Phe1047 
Vandetanib  Lys868, Glu885, Ile888, Leu889, 
Val899, Val916, Leu1035, Cys1045, 
Asp1046, Phe1047, Gly1048 
Vatalanib  Val848, Lys868, Glu885, Leu889, 
Val899, Val914, Val916, Leu1035, 
Cys1045, Asp1046, Phe1047 
Sorafenib Lys868 Leu840, Val848, Ala866, Glu885, 
Leu889, Val899, Val916, Glu917, 
Cys919, Phe918, Leu1035, Cys1045, 
Asp1046, Phe1047(2), Gly1048 
 
 
The hydrophobic amino acids of the intracellular domain of VEGFR1, which are engaged in the 
hydrophobic interactions with Puerarone, are Leu833, Val841, Ala859, Lys861, Leu882, Val892, 
Val907, Val909, Tyr911, Cys912, Gly915, Leu1029, Cys1039, and Phe1041. Within the 
commercial inhibitors, Vatalanib bound with the VEGFR1 intracellular domain more strongly 
than the others. Interestingly, the interaction profile of Vatalanib interacted hydrophobically with 
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Leu833, Ala859, Lys861, Leu882, Val907, Val909, Tyr911, Leu1029, Cys1039, and Phe1041, 
and formed hydrogen bonds with Glu878 which was similar to that of Puerarone. It is important 
to mention that Asp1040 residue of VEGFR1 was involved in hydrogen bond formation with 
Pazopanib, Axitinib, Vatalanib and Sorafenib. Lys861 forms a major amino acid residue of ATP 
binding sites in intracellular domain VEGFR1 and interestingly both, Puerarone and most of the 
inhibitors interacted with it. This provides us the clue that Puerarone may block the ATP binding 
site of VEGFR1, thus enforcing their inhibitory effect. 
Equivalently, Tuberostan was found to interact more effectively with the intracellular kinase 
domain of VEGFR2 through eleven hydrophobic amino acids, including Leu833, Lue840, 
Val848, Lys868, Glu885, Leu889, Val899, Val916, Phe918, Cys919, Lys920, Gly922, Cys1045, 
Asp1046, and Phe1047. Among the inhibitors, Axitinib showed the highest affinity for 
intracellular domain of VEGFR2. Both Tuberostan and Axitinib were found to share their 
hydrophobic interactions with Leu840, Val848, Lys868, Glu885, Leu889, Val899, Val916, 
Phe918, Cys919, Gly922, Cys1045, and Phe1047. Also, Tuberostan formed hydrophobic 
interaction with Asp1046, which on the contrary, was involved in the hydrogen bonding with 
Axitinib. Similar to VEGFR1, Lys868 forms a crucial residue for ATP binding in the case of 
VEGFR2 which was recognized to show hydrophobic bonding with Tuberostan and commercial 
inhibitors. Both the proteins as well as all the inhibitors showed hydrophobic interaction at the 
ATP binding site but Tuberostan, in addition, showed maximum hydrophobic interaction and 
highest binding affinity as per the LigPlot
+
 and Chimera analysis. Thus, making it better 
candidate for inhibition of intracellular domain of VEGFR2. The interaction profile of the 
phytochemicals with the VEGFRs using Autodock4.0, Chimera and LigPlot+, can be viewed in 
Fig 8. 
Asparagamine A, though showed less binding affinity with the VEGF receptors, but showed a 
very good hydrophobic interactions with Leu833, Val841, Ala859, Lys861 (active site) , Glu878, 
Ile881, Leu882, Ile885, Val892, Val907, Val909, Cys1018, Leu1029, Ile1038, Cys1039, 
Asp1040. Similarly with VEGFR2, Asparagamine A showed interactions with Val848, Ala866, 
Lys868 (active site), Glu885, Ile888, Leu889, Ile892, Val899, Val916, Leu1035, Ile1044, 
Cys1045, and Phe1047. 
LPGG showed hydrophobic interactions with VEGFR1, involving Thr877, Ile881, Ile885, 
Leu1013, Cys1018, Gly1042, and Leu1043. With VEGFR2, LPGG interacted with Leu840, 
36 
 
Val848, Ala866,   Lys868 (active site), Leu889, Val899, Val916, Cys919, Lue1035, Cys1045, 
Asp1046, and Phe1047. It can be observed that Asparagamine A and LPGG, both were having 
interactions with the active site, which can have a very crucial effect over the receptors, thus 
affecting angiogenesis. Due to the unavailability of Pueraria tuberosa, the work was continued 
with Asparagus racemosus and Ficus benghalensis. 
 
 
 
Figure 8. Interaction Profile of phytochemical Asparagamine A and Leucopelargonidin 3-o-glucoside 
with VEGF receptors using Chimera and LigPlot+ 
 
2.2.2. Extraction of Phytochemicals:  
The plant was taken and the extraction of the plant was done using soxhlet apparatus. The extract was 
dried in vacuum evaporator and stored. For this purpose, the extraction was done using the soxhlet, 
commonly known as the solvent extraction. This solvent extraction is a procedure that can be used to 
detach or isolate the sample from the plant containing many other impurities. Choice of solvent is 
based on the phytochemicals required from the plant. Asparagus racemosus and Ficus benghalensis 
were extracted using methanol as well as aqueous solvents [109]. 
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Figure 9: Extraction of phytochemicals from Asparagus racemosus using soxhlet method 
 
The plant extracts do not have only one phytochemical but have a mixture of many. For having 
expected phytochemicals were examined for their presence using the biochemical tests which is 
tabulated in Table 13. 
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Table 13: Phytochemical analysis of the plant extracts of Asparagus racemosus and Ficus 
benghalensis 
S.NO NAME OF THE TEST 
EXPECTED 
COLOUR 
RESULT 
Asparagus 
racemosus 
Ficus 
benghalensis 
1 Test for carbohydrates Reddish Colour ++ ++ 
2 Test for tannins Dark Blue Colour - - 
3 Test for alkaloids Yellow colour ppt +++ ++ 
4 Test for Flavonoids Yellow Colour +++ +++ 
5 Test for terpenoids 
Reddish Brown at 
interface 
+ - 
6 Test for saponins Foam appears - + 
7 Test for quinines Red Colour - + 
8 Test for steroids 
Brown ring at 
interface 
+ + 
*
+++ Highly present ;  ++ Moderately present ;  - not present 
 
2.2.3. Cell proliferation assay: 
After the complete biochemical analysis, the phytochemicals are needed to be tested for the amount it 
should be used. There two different sets of different concentrations were taken. MTT assay was done 
to check the cell proliferation in the presence of the extract. These were compared for their relative 
proliferative index in which it was found that the concentration at micrograms are more compatible 
for the cells and even help in the cell proliferation. The cells were found to die at higher 
concentrations of the phytochemicals. The concentrations found through the in silico analysis was 
confirmed here as the Ki values of these plants are also equal and less than the µM concentrations. 
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Figure 10: Optimization of the concentration of the phytochemicals for their effect over the cell 
proliferation. Asparagus racemosus: A1=1mg/ml; A-1= 10
-1
mg/ml; A-2=10
-2
mg/ml; 
A-4=10
-4
mg/ml; A-6= 10
-6
mg/ml. Ficus benghalensis: B1=1mg/ml; B-1= 10
-1
mg/ml; B-2=10
-
2
mg/ml; B-4=10
-4
mg/ml; B-6= 10
-6
mg/ml. 
 
 
 
Figure 11: Cell proliferation in the presence of the microgram concentration of the plant extract. 
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It was observed that at high concentration of the extract, the cell started dying after 4
th
 day of cell 
proliferation. On the other hand, the low concentration of the extract initiated the proliferation of 
the cells very well. The dilutions of the concentration till the microgram concentration were done 
as the required phytochemical Asparagamine A and LPGG obtained from the in silico study, had 
Ki in micromolar concentrations. In silico study was confirmed and was identical with the one 
prepared in vitro. Though it was a crude extract but the concentration was maintained at around 
microgram which was not toxic to the cells, rather it enhanced the rate of proliferation. The 
proliferation of cells which usually takes 6-7 days to become completely confluent but it was 
completed in 4days. The samples having lowest concentration of the extract was found to 
support the cell proliferation. It can also be estimated that more the proliferation of cells, more is 
the secretion of growth factors like VEGFs and FGFs, more is the angiogenic potential. But still 
the optimization of angiogenic potential is need through the VEGF expression assay. 
  
 
CONCLUSION: 
In this complete study in silico was done to elucidate the medicinal potentials of the 
phytochemicals derived from herbal plants. The overall analysis suggested that Asparagamine A 
and Leucopelargonidin 3-o-glucoside could show good affinity towards the critical proteins 
VEGFR1 and VEGFR2 respectively. The study provided a new direction for the designing and 
development of a novel drug against VEGFRs for the treatment of multiple angiogenic diseases; 
thus using the pharmacological aspects of these compounds. Further, In vitro and In vivo study 
over the cell proliferation proved it to be non toxic at the level of microgram/ ml concentration, 
thus initiating a good proliferation rate than the usual rate, without the involvement of the 
phytochemicals. In vitro as well as in vivo validation of the estimated mechanism as well as the 
therapeutic potentials of the selected phytochemicals is required through the VEGF expression 
assay. 
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III. INSUFFICIENT ADIPOGENESIS 
 
Adipose tissue is not only known for its abundance in the human body but also as a major 
reserve for energy, and storage of triacylglycerol. Adipose tissue includes cells known as 
adipocytes along with the fibroblast cells, smooth muscle cells, endothelial as well as adipogenic 
progenitor cells. These adipocytes which are specialized cells for adipose tissue, release various 
growth factors that are important in the regulation of many pathways. The pre-adipocyte 
differentiation upto mature adipocyte is due to the regulation of two major factors, C/EBPs and 
PPARγ. In addition, Peroxisome Proliferator activated receptors as well as the CCAAT/ 
enhancer binding protein; both regulate each other also [110-112].  
Among all, PPARγ is important for adipogenesis as it not only affect the differentiation of the 
preadipocytes but also initiate the storage of fatty acids in the differentiated adipocytes. PPARγ 
is present in two isoforms- γ1 and γ2. Though γ1 is expressed in majorly all the tissues but still it 
plays fewer roles in adipogenesis as γ2. Recently it has been found that the over-expression of 
the latter, can lead to disorders like Cancer, Obesity. On the contrary, the problems like severe 
burns or in traumatic wound, healing is required and at that time there is need of adipogenesis, 
especially in deep wounds or deep burns.  
In the current study, the in –silico analysis was tried to test the effect of the phytochemicals over 
the adipogenesis through the molecular docking analysis of these phytochemicals with PPARγ.  
 
3.1. MATERIALS AND METHODS 
3.1.1. Protein structure retrieval: 
Protein Data Bank was used to retrieve the three dimensional crystal structures of the target 
protein (http://www.rcsb.org/pdb/). Table 1 lists the proteins studied for the targeted disease. 
Removal of miscellaneous ligands and other hetero-atoms such as water molecules, ions, atoms, 
etc. was done from the protein models for a better active site predictions and analysis, followed 
by further docking studies using Argus Lab Software. 
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3.1.2. Protein Active Site Predictions: 
CASTp Calculations (Computed Atlas of Surface Topography of proteins) were used for 
predicting the active sites of the target proteins. Amongst the predicted site, the site having the 
catalytic amino acids was chosen for the docking of the ligand. The catalytic amino acids of the 
each protein were analyzed from UniProt (http://www.uniprot.org/). 
 
3.1.3. Substrate selection: 
The three dimensional structure of Asparagamine A was screened from KNApSAcK-3D database 
(http://knapsack3d.sakura.ne.jp/). The PDB structure of the ligand was deduced using PRODRG 
Server (davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg). Optimization of the ligands and the 
minimization of their energy were done using Argus lab software. Besides, the standard or 
reference molecules were also evaluated. For which, the three dimensional structures of standard 
molecules for all the aforesaid proteins were also deduced from PubChem database 
(http://pubchem.ncbi.nlm.nih.gov/) and were used as reference molecules. 
 
3.1.4. Molecular Properties and Drug likeness: 
The Asparagamine A was further examined for its drug likeness and molecular properties using 
FAF-Drug2 (http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py?form=FAF Drugs#forms:: 
FAF- Drugs2) and PreADMET (http://preadmet.bmdrc.org/). 
 
3.1.5. Molecular Docking: 
The computational docking of Asparagamine A and standard inhibitors were performed into the 
active site of corresponding protein models using AutoDock4.2 software (version 1.5.6). While 
docking, polar hydrogen’s were added to protein models using the hydrogen’s module and 
thereafter, Kollman united atom partial charges were assigned. Docking of ligand was carried out 
using Lamarckian Genetic Algorithm with standard docking protocol on the basis a population 
size of 150 randomly placed individuals; a maximum number of 2.5*10
7
 energy evaluations, a 
mutation rate of 0.02, a crossover rate of 0.80 and an elitism value of 1 [113]. Fifteen independent 
docking runs were carried out for each ligand and results were clustered according to the 1.0 Ǻ 
rmsd criteria. The grid maps representing the proteins were calculated using autogrid and grid size 
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was set to 60*60*60 points with grid spacing of 0.375 Ǻ. The coordinate of the docked protein 
along with the ligand was visualized using UCSF chimera and LigPlot
+
 [114]. 
 
3.2. RESULTS AND DISCUSSION: 
The molecular docking analysis was done which gave the top binding ligands which were further 
compared with the standard known drug molecules. 
From the docking analysis of the phytochemicals with PPAR γ, it was found that previously 
selected phytochemicals gave very good results with PPAR γ as well. Chimera analysis showed 
the binding interactions which revealed the hydrogen interactions which the ligands made with 
the protein (Table 14). Asparagamine A, a unique phytochemical present in Asparagus 
racemosus showed the binding of -9.90Kcal/mol with Ki 0.522 µM. This ligand showed 
interactions with PPAR γ involving Cys285, Glu286, Ser289, His323, and Tyr473. LPGG 
showed less but effective binding affinity of -7.60 Kcal/mol (Ki: 2.67) with PPAR γ involving 
Ser289, and His 323. 
Table 14: Binding interaction of PPAR gamma with selected phytochemicals. 
PDB 
ID 
Ligands 
Minimum 
Binding 
Energy 
(kcal/mol) 
Ki 
(µM) 
Interacting Amino 
Acids 
3ET3 
Asparagamine A -9.90 0.522 Cys285, Glu286, 
Ser289, His323, Tyr473 
Quercitrin -9.52 0.105 
Cys285, Gln286, 
Ser289, Tyr327 
Leucopelargonidin 
3-o glucoside 
-8.38 2.06 Ser289, His 323 
Isoquercitrin -7.60 2.67 
Ser 289, 
Phe360,Tyr473, His449 
 
Similarly, Isoquercitrin commonly found in Centella asiatica (Mandukaparni) showed binding of 
-8.38Kcal/mol (Ki: 2.06) through amino acids Ser 289, Phe360, Tyr473,  and His449 . Centella 
asiatica is also known as Brahmi, is majorly used in lesions and infections. It is also used as 
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wound healer. Quercitrin which is mainly found in Cressa cretica as well as Centella asiatica 
mentioned above, showed binding affinity of -9.52Kcal/mol (Ki: 0.105). This ligand interacted 
with the protein Cys285, Gln286, Ser289, and Tyr327. Cressa cretica is also one of a medicinal 
plant, known as Rudravanti is famous for its therapeutic properties for treating asthma, diabetes 
and skin diseases. LigPlot+ analysis revealed the hydrophobic interactions of ligands with 
PPARγ that can be viewed in table 15.  
 
Table 15: Molecular interactions of PPAR gamma with phytochemicals revealing the hydrogen 
and hydrophobic interactions using LigPlot+ 
PDB 
ID 
Ligands 
Hydrogen Bond 
Interaction 
Hydrophobic interaction 
3ET3 
Asparagamine 
A 
Cys 285, 
Glu286, Ser289, 
His323, Tyr473 
Ile281, Phe282, Arg288, Ile326, 
Tyr327, Leu330, Leu353, Leu256, 
Phe363, Met364, Lys367, Leu465, 
Leu469 
Quercitrin 
Cys285, Gln286, 
Ser289, Tyr327 
Ile281, Phe282, Ile326, Arg288, 
Leu330, Leu356, Phe363, Met364, 
Lys367, His449,  Leu465, Leu469, 
Leucopelargoni
din 3-o 
glucoside 
Ser289, His 323 
Phe282, Cys285, Ile326, Tyr327, 
Leu330, Val339, Ile341, Met364, 
Lys367, His449, Leu453, Leu465, 
Leu469, Tyr473 
Isoquercitrin 
Ser 289, 
Phe360,Tyr473, 
His449 
Ile281, Arg288, Phe282, Ile326, 
Leu330, Leu356, Phe363, Met364, 
Lys367, His449, Leu465, Leu469 
 
The analyzed ligands were also compared with the reference molecules which proved the 
phytochemicals as an effective ligand for PPARγ. The binding interactions for the reference 
molecules can be viewed in table 16. 
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Table 16: Binding interaction of PPAR gamma with standard molecules. 
 
Proteins Reference molecule 
Minimum Binding 
Energy (Kcal/mol) 
Ki (M) 
PPAR 
MK886 [115] -9.28 0.158 
Thiazolidine-2,4-
dione [116] 
-4.01 1140 
 
The binding pattern or the interaction profile of all the ligands were noted and can be viewed in 
figure 11. This analysis involved the use of Chimera and LigPlot+ for the hydrogen bonds and 
hydrophobic interaction study. 
 
Figure 12: Interaction profile of the phytochemicals from with PPAR gamma: (A) – 
Asparagamine A; (B) – Isoquercitrin; (C) – Quercitrin; (D) – Leucopelargonidin 3-o-glucoside 
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3.3. CONCLUSION: 
In adipogenesis, the in silico analysis was done in which the top 4 molecules were selected. Out 
of which the Asparagamine A and Leucopelargonidin 3-o-glucoside were also there. It can be 
estimated that these two can have a significant effect over the adipogenesis also, which can only 
be confirmed through the in vitro and vivo analysis. This in vitro and in vivo analysis can be 
done through the study of adipogenic differentiation for which optimization is required. 
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IV. SPECIAL TYPES OF CHRONIC ULCERS 
 
Asparagus racemosus belongs to the family of Asparagaceae and is famous as Shatavari, is found 
in tropical and subtropical regions of Asia, Africa and Australia [117]. In traditional medicinal 
systems like Ayurveda, Unani and Siddha, this endangered plant has been reported to possess 
potential to treat variety of diseases and disorders. The plant is widely known for its excellent 
rejuvenating activity on female reproductive system.  In addition ,the  extracts from various parts 
of this plant is also well known to possess anti-ulcer, anti-bacterial, anti-depressant, anti-
inflammatory, antiprotozoal, antiviral, antioxidant and anticancer properties [117-120]. Such a 
great variety of therapeutic usefulness of this plant is due to the wide variety of phytochemicals 
present in it. The major phytochemicals present in the Asparagus racemosus includes Shatavarins 
(I-IV), Idaein, Immunoside, Racemosides, Diosgenin, Sarasasapogenin and Asparagamine A etc. 
[117, 119-121]. Among these, Shatavarin IV has already been known to have anti-cancerous 
activity [122]. Keeping in view, the wide therapeutic activity of Asparagus racemosus, not much 
work has been done to attribute these therapeutic benefits to any specific phytochemical. 
Interestingly, when the structures of all the phytochemicals of this plant were evaluated, 
Asparagamine A, a polycyclic pyrrolizidine alkaloid, found to have a very unique cage like 
structure [123-124]. Though this unique structured Asparagamine A was isolated and 
characterized two decades ago by Sekine et.al., yet not much have been reported about its 
potential activities in the scientific literatures [123]. This compound has been reported to possess 
excellent antioxidant, anti-oxytocin, antitumor activities [124-126], but the effectiveness and 
efficacy of the compound was never evaluated over wide range of diseases against which 
asparagus racemosus has shown therapeutic benefits. In the present study, we have tried an In 
Silico approach to explore the therapeutic potentials of Asparagamine A over osteoporosis, AIDS, 
Tuberculosis, Cancer, Malaria, Leishmaniasis and Trypanosomiasis. The critical proteins which 
are considered to be essential for the development and progression of these diseases were isolated 
computationally and were docked with Asparagamine A using AutoDock4.2 tool (version 1.5.6). 
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4.1. MATERIALS AND METHODS 
 
4.1.1. Protein structure retrieval: 
The three dimensional crystal structures of target proteins were retrieved from Protein Data Bank 
(http://www.rcsb.org/pdb/). The proteins selected for targeting the diseases have been compiled in 
Table 1. Miscellaneous ligands and other hetero-atoms such as water, ions, etc. were removed 
from the protein models for active site predictions and further docking studies using Argus Lab 
Software. 
 
4.1.2. Protein Active Site Predictions: 
The active sites of target proteins were predicted by using CASTp Calculations (Computed Atlas 
of Surface Topography of proteins). Amongst the predicted site, the site having the catalytic 
amino acids was chosen for the docking of the ligand. The catalytic amino acids of the each 
protein were analyzed from UniProt (http://www.uniprot.org/). 
 
4.1.3. Substrate selection: 
The three dimensional structure of Asparagamine A was screened from KNApSAcK-3D database 
(http://knapsack3d.sakura.ne.jp/). The PDB structure of the ligand was deduced using PRODRG 
Server (davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg). Ligand optimization and energy 
minimization was further done using Argus lab software. Apart from this, the three dimensional 
structures of standard inhibitors for all the aforesaid proteins were also deduced from PubChem 
database (http://pubchem.ncbi.nlm.nih.gov/) and were used as reference molecules. 
 
4.1.4. Molecular Properties and Drug likeness: 
The Asparagamine A was further examined for its drug likeness and molecular properties using 
FAF-Drug2 (http://mobyle.rpbs.univ-paris-diderot.fr/cgi-bin/portal.py?form=FAF Drugs#forms:: 
FAF- Drugs2) and PreADMET (http://preadmet.bmdrc.org/). 
 
4.1.5. Molecular Docking: 
The computational docking of Asparagamine A and standard inhibitors were performed into the 
active site of corresponding protein models using AutoDock4.2 software (version 1.5.6). While 
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docking, polar hydrogen’s were added to protein models using the hydrogen’s module and 
thereafter, Kollman united atom partial charges were assigned. Docking of ligand was carried out 
using Lamarckian Genetic Algorithm with standard docking protocol on the basis a population 
size of 150 randomly placed individuals; a maximum number of 2.5*10
7
 energy evaluations, a 
mutation rate of 0.02, a crossover rate of 0.80 and an elitism value of 1 [113]. Fifteen independent 
docking runs were carried out for each ligand and results were clustered according to the 1.0 Ǻ 
rmsd criteria. The grid maps representing the proteins were calculated using autogrid and grid size 
was set to 60*60*60 points with grid spacing of 0.375 Ǻ. The coordinate of the docked protein 
along with the ligand was visualized using UCSF chimera and LigPlot
+
 [114]. 
 
4.2. RESULTS & DISCUSSIONS 
Millions are being affected and millions are dying each year because of the diseases like AIDS, 
malaria, tuberculosis and Leishmaniasis. A number of drugs exist commercially that could be 
used for treatment of these diseases. But still the search of new lead molecules and drugs 
continues because of the side-effects posed by the existing drugs; emergence of the drug resistant 
forms of microorganisms and the need to develop drug with better efficacy and potency. The 
drugs developed against the above mentioned diseases are usually targeted towards some of the 
crucial proteins associated with the diseases or the causative microorganisms. The drugs and the 
corresponding proteins that they inhibit and hence have beneficial effect in these diseases are 
mentioned in the Table 15. In this study, Asparagamine A was targeted against those proteins to 
analyze its inhibitory effect over aforesaid diseases and the result was compared with the 
inhibitory efficiency of standard inhibitors.  
 
Table 17: Potential Drug targets to target various diseases 
Diseases Proteins Notations Organism PDB ID Ref. 
Tuberculosis Mycolic Acid Cyclopropane 
Synthase 
CmaA2 Mycobacterium 
tuberculosis 
1KPI [127] 
PKnB Kinase Domain PKnB Mycobacterium 
tuberculosis 
1O6Y [128] 
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HIV 1 HIV1 Protease H1P HIV 1AJV [129] 
Leishmaniasis Trypanothione Reductase LTR Leishmania 
infantum 
2JK6 [130] 
 
 
ADME & Toxicity predictions were initially done to evaluate the pharmacokinetics and the 
toxicity of the phytochemicals/ligands. These predictions demonstrated that Asparagamine A did 
not have any mutagenicity and carcinogenicity. Asparagamine A was found to follow Lipinski’s 
rule of five which allow the evaluation of pharmacokinetics of the drug including absorption, 
distribution, metabolism and excretion (ADME). The predicted percentage absorption of 
Asparagamine A through oral route was found to be 90.94%. High absorption of the drug allows 
it to achieve high concentration at the target site. Also the chemical was found to bind with 
plasma proteins weakly, making the majority of the unbound molecules available for diffusion, 
distribution and deposition across the body. The molecular properties as well as the three and two 
dimensional structure of Asparagamine A are mentioned in Table 17 and Figure 12 respectively. 
 
Table 18: Molecular Properties of Asparagamine A 
 
MOLECULAR PROPERTIES 
Molecular Weight 385.45 
Log P 2.24 
Log Sw -3.44 
tPSA 66.02 
HB Donors 1 
HB Acceptors 6 
Lipinski’s Violations 0 
Solubility (mg\l) 12322.28 
Oral Bioavailability (VEBER) Good 
Oral Bioavailability (EGAN) Good 
AMES Test Non Mutagen 
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Carcinogenicity Non Carcinogen 
Human Intestinal Absorption (%) 90.947 
In Vitro Plasma Protein Binding (%) 44.936 
 
 
 
 
 
 
 
Figure 13: Three dimensional (A) and two dimensional (B) structure of Asparagamine A. 
 
Molecular docking using the computational approach has been demonstrated as an effective 
methodology to analyze the interaction patterns of the ligand molecules with the proteins models.  
The interaction of drug with protein could bring some structural changes that may change or 
block its potential activity. A known fact is that the active site of protein plays a critical role in 
protein’s activity and the computational designed drugs, usually targets these active sites.  
Docking analysis revealed that Asparagamine A possesses a very high affinity towards the HIV-
1 proteases with estimated Ki values of 4.58 nM respectively.  Both these proteins belong to the 
class of aspartic proteases and are usually targeted for drug designing against malaria and AIDS 
respectively [131-132]. HIV-1 protease catalyzes the proteolytic breakage of the polypeptide 
precursors into mature enzymes and structural proteins of the virus [133]. 
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HIV infection has significantly contributed to worldwide re-emergence of tuberculosis incidences. 
With the development and evolution of the multi drug resistant (MDR) as extensively drug 
resistant (EDR) strains of Mycobacterium tuberculosis has drawn much of the attention towards 
the development of novel drugs [134-135]. In this regard, it is desired to design lead molecules 
that can simultaneously target both the diseases. Interestingly, Asparagamine A showed a binding 
energy of -9.48Kcal/mol and -8.54Kcal/mol towards CmaA2 and PKnB respectively; which have 
recently been identified as potential drug targets to combat tuberculosis [127-128]. CmaA2 is 
known to be a trans–cyclopropane synthase for both the methoxy- and keto- mycolates which are 
the major components of the cell envelope of M. tuberculosis and helps in the interaction of these 
bacteria with the human host [136]. PKnB is known as a functional kinase which gets  
autophosphorylated on serine/ threonine residues and is also capable of the phosphorylation of the 
myelin basic protein which is the main peptide substrate [137]. 
Another protein Trypanothione Reductase (TR) is unique to Leishmania and absent from 
mammalian cells, is considered as a potential drug target to combat Leishmaniasis [130, 138]. The 
Asparagamine A was found to have high affinity towards Trypanothione Reductases derived from 
both, Leishmania infantum (Ki: 17.75 nM) with estimated binding energies of -10.57 Kcal/mol. 
It is highly desirable that a ligand must possess a high affinity for the protein to modulate the 
protein activity. The affinity of the ligand for the protein correlates with the binding energy of the 
protein ligand complex. Thus, lower the binding energy of the complex, higher the affinity of the 
ligand for the protein. The analysis of ligand’s affinity towards the protein is insufficient to 
predict stable docking. Thus, it is essential to analyze the complete interaction profile of ligand 
with amino acid residues of the protein. The interactions that are usually accounted for in protein-
ligand complex are hydrogen bonds and hydrophobic interactions. The presence of these 
hydrogen bonds and hydrophobic interactions increases the stability of protein ligand complex. In 
this regard, the probable hydrogen bonds and hydrophobic interactions formed between proteins 
and Asparagamine A was illustrated through Chimera (Table 18) and LigPlot
+
 (Table 19). The 
interaction can be viewed in Figure 13. 
 
Table 19: Binding Interactions of Asparagamine A – Docking and Chimera Analysis: 
Proteins 
Minimum Binding  
Energy (Kcal/mol) 
Ki (nM) 
Hydrogen  
Bonds 
Interacting Amino Acids 
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CmaA2 -9.48 111.94 0 - 
PKnB -8.54 553.05 3 Lys40 (2), Asp156 
H1P -11.38 4.58 2 Ile50, Asp128 
LTR -10.57 17.75 6 
  Thr51, Asp327 (3), Met333,  
Thr335, 
 
 
Table 20: Molecular Interactions of Asparagamine A – LigPlot+ Analysis: 
Proteins Interacting Amino Acids via 
Hydrogen Bonds Hydrophobic Interactions 
CmaA2 - Tyr24, Tyr41, Gly145, Ile184, Ile210,  
Leu211, Phe215, Gly218, Leu220,  
Tyr247, Trp254, Tyr280,Cys284, Phe288 
PKnB Lys40, Asp138, Asp156 Phe19, Gly20, Met22, Ser23, Val25, 
 Met155, Gly158, Thr159 
H1P Asp 124, Asp 128, Ile50 Asp25, Gly27,Ala28,Gly48, Gly49, Gly126, 
Ala127, Asp129, Val131, Ile146, Gly147,  
Ile149,Pro180,Val181, Ile183 
LTR Asp327 (2), Thr335 Gly13, Ser14, Gly50, Thr51, Cys52, Gly56, 
Cys57, Ala159,  Gly161, Ser162, Tyr198, 
Arg287, Gly326, Met333, Leu334 
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Figure 14: Molecular interactions of Asparagamine A- UCSF Chimera & LigPlot
+
: (A) - CmaA2 
(Tuberculosis); (B) - PKnB (Tuberculosis); (C) – H1P (AIDS); (D) – LTR (Leishmaniasis) 
 
A comparative analysis of the binding affinity of Asparagamine A and the reference molecules 
towards the corresponding proteins suggested that the alkaloid Asparagamine A could be 
developed into potential therapeutic agent for the treatment of many diseases (Table 20 and 21). 
The analogues of Asparagamine A could also be developed for the improvement of its specificity 
and affinity towards a protein target. The chemical synthesis of Asparagamine A was reported by 
Brüggemann M. et.al., also makes it a suitable candidate for much desirable mass scale 
production of the ligand and its analogues [139]. 
 
Table 21: Binding Energy of Reference Inhibitors (Standard drugs): 
Proteins Inhibitors 
Minimum Binding 
Energy       (Kcal/mol) 
Ki (nM) 
CmaA2 Thioacetazone [127] -6.26 26000 
PKnB 2,4-Dichloroquinazoline [128] -4.75 330000 
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H1P 
 
Indinavir [129] -11.17 6 
Amprenavir [129] -9.62 89 
LTR Ebsulfur [140] -6.96 7970 
 
Table 22: Comparison between the standard drugs with Asparagamine A  
Proteins Inhibitors 
Ki (nM)  
[Standard drugs] 
Ki (nM)  
[Asparagamine A] 
CmaA2 Thioacetazone 26000 111.94 
PKnB 2,4-Dichloroquinazoline 330000 553.05 
H1P Indinavir 6 4.58 
 
Amprenavir 89 4.58 
LTR Ebsulfur 7970 17.75 
 
 
4.3. CONCLUSION 
The complete study was conducted in silico to explore the therapeutic potentials of the ligand 
Asparagamine A derived from A. racemosus. The overall analysis suggests that Asparagamine A 
shows a higher affinity towards the critical proteins that are generally targeted to combat aforesaid 
mentioned diseases. The study provides a clue for the development of a new lead that could be 
used for the prevention or cure of multiple diseases. Further, In vitro and In vivo validation of 
aforesaid therapeutic potentials of Asparagamine A is required. 
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V. CHRONIC INFLAMMATION 
 
Wound healing initially begins with the inflammation in which the blood vessels dilate and 
neutrophils infiltrate into the injury site. Macrophages are released which release inflammatory 
cells as well as more of macrophages. These inflammatory cells cause inflammation in the area 
of the injury. Apart from the inflammation due to these cells, the reasons mentioned in all the 
chapters, involve the development of severe (chronic) inflammation and persistence of the 
wounds for a long period of time.  
Inflammation itself is of two types: Acute and chronic inflammation. On one side, acute 
inflammation is there which is quite regulated but chronic inflammation is completely 
dysregulated. Inflammation usually begins in a controlled manner so as to protect the body from 
the infection but it can change its path to an unregulated one. This leads to the chronic phase of 
inflammation. Normal process of wound healing continues but the cell composition changes. 
Chronic inflammation is one of a major problem being faced today. This leads to delayed healing 
of severe wounds, diabetes, ulcers [141-142]. Apart from this, chronic inflammation also affects 
the arteries and the blood vessels which can cause Heart attack, Cancer, etc [143-144]. 
A major polyphenol phytochemical present in turmeric, which is known as Curcumin 
(C21H20O6), is a yellow pigment from Curcuma longa. This is used as the food colouring agent 
and also used in cosmetics and in medical preparations. Therapeutic potentials of curcumin 
include majorly its antioxidant, anti – inflammatory properties [145]. The mechanism of its 
properties includes the down regulation of the role played by major enzymes, namely 
cyclooxygenase -2 (COX-2), nitric oxide synthase (iNOS). Along with this, there is a decrease in 
the release of Tumor necrosis factor – alpha (TNF-α), interleukins (IL) and major inflammatory 
cytokines. Curcumin is known to subdue the activity of nuclear factor kappa beta (NF-κβ) which 
in turn inhibits COX-2 and iNOS. This NF- κβ is a transcription factor which takes part in the 
regulation of inflammation, cellular proliferation, and tumorogenic behavior [146-147].  
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Curcumin is important not only in inflammation, but also in the many chronic pathological 
diseases like cancer, atherosclerosis, etc.  Curcumin shows its anti- cancerous activity by 
affecting the cell cycle and mutagenic pathways, etc [148]. The down regulation of the 
transcription factors, interleukins related to the disorder lead to the anti – proliferation of the 
tumorogenic cells [149]. 
 
5.1. MATERIAL AND METHODS: 
5.1.1. Drug release kinetics: 
The polymer – ECM composite films were used for the drug release analysis by incorporating 
curcumin inside the films. The films were kept in a tube whose cap was covered with dialysis 
membrane and the whole system was dipped in PBS. The fixed volume of PBS was taken at 
regular interval of time of 15 min, 30 min, 45 min, 1 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr, 8 hr, 12 hr, 24 
hr, 48 hr, 72 hr, 96 hr, 120 hr, and 144 hr. The volume was made constant by replacing it with 
fresh PBS. The absorbance of all the samples was taken at 420 nm [150].  
 
 
Statistical Analysis:  
Each experiment was performed in triplicates. All the results were mentioned as the average 
(mean) ± S.D. Statistical analysis of all the quantitative data was done using one – way ANOVA 
through IBM SPSS Statistics 20.0. The results of all the samples were compared at 95% of 
confidence level. The results with p – value equal or less than 0.05 were considered to be 
statistically significant. 
 
RESULTS AND DISCUSSION: 
Drug release kinetics: 
The release of drug was recorded at the regular interval of time by measuring the absorbance at 
570 nm. A comparative slow release was observed in the composites when compared with the 
chitosan or alginate control samples. This may be due to the cross-linking of the curcumin with 
the ECM. This is even better if the films are to be used for the wound healing purpose. 
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Figure 15. Drug release kinetics in Chitosan – Extracellular matrix and Alginate – Extracellular 
matrix composite films 
 
The main purpose of adding curcumin into the prepared film was to prepare such a scaffold 
which has a drug which act majorly against inflammation due major diseases. Curcumin being a 
phytochemical available in pure form was taken. The comparison among different films was 
done after incorporating the phytochemical. It was good to observe that there was a very slow 
and steady release of drug from the film as compared to the control. It may be due to some 
crosslinking with the extracellular matrix which is making it to release out slowly. 
Since Curcumin also inhibit adipogenesis, so it cannot be used for the deep wounds where there 
is complete loss of adipose tissue as those effected regions need the restoration of adipose tissue. 
The wounds which are superficial and need re-epithelialization rather than adipogenesis, there 
these films along with curcumin can be efficiently used. 
 
CONCLUSION: 
The biological and medicinal property of curcumin makes it beneficial for the treatment of the 
chronic wounds. The films prepared were tested for their role in the superficial burns by 
incorporating curcumin in it. Curcumin, added to the films made the film very stiff and strong, 
that is, with high mechanical strength. This is due to the fact that curcumin cross-links with ECM 
and polymer, thus causing slow release of drug.  
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